Highlights 

  • Tradipitant reduces GLP-1–related vomiting by 50% in a randomized controlled study. 
  • The therapy significantly lowers combined nausea and vomiting rates compared to placebo. 
  • Study design mimicked a rapid titration to 1 mg Wegovy®, bypassing the usual 9-week escalation. 
  • Safety profile aligned with previous trials with no new concerns reported. 
  • Findings position tradipitant as a potential key adjunct in the global GLP-1 agonist market valued at over USD 50B. 

Vanda Pharmaceuticals Inc. (Nasdaq:VNDA) announced encouraging topline results from its randomized, double-blind, placebo-controlled study evaluating tradipitant for preventing nausea and vomiting triggered by GLP-1 receptor agonist therapy. The study examined adults who were overweight or obese and had no prior GLP-1 agonist exposure. 
Participants were pretreated with tradipitant or placebo before receiving a full 1 mg injection of Wegovy®—a dose typically reached only after nine weeks of titration under current prescribing guidance. The goal was to replicate a high-intensity initiation scenario that frequently leads to gastrointestinal side effects and early therapy abandonment. 

Marked Reduction in Vomiting and Improved Tolerability 

The study met its primary endpoint with a notable reduction in vomiting: 29.3% of participants treated with tradipitant experienced vomiting compared to 58.6% on placebo, amounting to a 50% relative reduction (p=0.0016). 
The key secondary endpoint also showed positive differentiation. Only 22.4% of the tradipitant group reported both vomiting and moderate-to-severe nausea (score ≥3), versus 48.3% in the placebo arm (p=0.0039). 
Safety profiles for tradipitant remained consistent with earlier studies, with no new safety issues emerging. These results align with the compound’s previously demonstrated impact in motion sickness studies, where tradipitant lowered vomiting incidence by more than half across trials involving over 800 individuals. 

Implications for the Expanding GLP-1 Agonist Market 

With the global GLP-1 agonist market surpassing USD 50B in the first nine months of 2025, improving tolerability has become critical for sustained therapy success. Gastrointestinal side effects remain the leading cause of discontinuation, with real-world data showing 30–50% of patients stopping treatment prematurely. 
Reducing these early drop-offs may unlock major health gains such as consistent 15–20% weight loss and improved cardiometabolic outcomes. It can also help payors avoid spending on unused prescriptions and reduce long-term costs associated with untreated obesity. 
Vanda expects to engage with regulatory authorities and is planning a Phase III program targeted to begin in the first half of 2026, aiming to bring a preventive option to patients initiating GLP-1 therapies. 

Conclusion 

The positive clinical findings for tradipitant underscore its potential to enhance patient tolerability and persistence with GLP-1 therapies. By mitigating the nausea and vomiting often associated with early dosing, tradipitant may meaningfully improve patient outcomes and support broader, sustained use of GLP-1 agonists. Vanda’s planned Phase III program will clarify the therapy’s regulatory path and its future role in the rapidly expanding metabolic-health treatment landscape. 

Also read - Incyte (NASDAQ:INCY) CHMP Recommends Minjuvi Combo for Second-Line FL Treatment